Back to results
US 2019/0337934 A1Published application
Rip1 inhibitory compounds and methods for making and using the same
AssigneeRigel Pharmaceuticals, Inc.
InventorsVanessa Taylor, Jiaxin Yu, Esteban Masuda, Ihab Darwish, Yan Chen
Life of this patent
Estimating the term…
Abstract
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to inhibit a RIP1 kinase in vivo or ex vivo, and also may treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
Claims21
A compound, having a formula
- or a pharmaceutically acceptable salt thereof, wherein:
- ring B is 5-membered heteroaryl;
- L is a C1-10aliphatic linker;
- R1 is Ra or Rb wherein at least one R1 is Rb;
- each of R2 and R3 independently are Ra;
- each R4 and each R5 independently are Ra or Rb;
- Ra is independently for each occurrence H, D, C1-10aliphatic, or C1-10cycloaliphatic;
- Rb is independently for each occurrence halogen or —NRdRd wherein (i) each Rd independently is Ra or Re;
- or (ii) two Rd groups together with the nitrogen bound thereto provide a C3-10heterocyclic group;
- Re is independently for each occurrence —ORa, —NRa, C1-6alkyl, C1-6haloalkyl, C1-6heteroalkyl, C3-6cycloalkyl, or two Re groups join together to provide a C3-10heterocyclic group with the Rb group to which the two Re groups are bound;
- m is 1 to 4;
- n is 0, 1 or 2;
- and
- p is 0, 1, 2, 3, 4, or 5.
11 more elements
Dependencies are inferred from the claim text.